Biotechnology: Biological Products (No Diagnostic Substances)

Clinical TrialApr 22, 2026, 04:07 PM

Fennec: 4 PEDMARK Abstracts Accepted for 2026 ASCO Meeting

AI Summary

Fennec Pharmaceuticals announced that four abstracts evaluating its drug PEDMARK® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This highlights growing clinical interest in addressing cisplatin-induced hearing loss, which PEDMARK aims to treat. The presentations will take place from May 29 to June 2, 2026, in Chicago.

Key Highlights

Four abstracts evaluating PEDMARK accepted for 2026 ASCO Annual Meeting.
PEDMARK addresses cisplatin-induced hearing loss.
ASCO meeting to be held May 29-June 2, 2026, in Chicago.

View SEC Filing

FENC

Biotechnology: Biological Products (No Diagnostic Substances)

FENNEC PHARMACEUTICALS INC.

Price Impact